Article - Wharton Management Department
... BRCA1 or BRCA2 mutations: chemoprevention (tamoxifen for breast cancer and oral contraceptives for ovarian cancer), prophylactic surgery (bilateral mastectomy for breast cancer and bilateral salpingo-oophorectomy for ovarian cancer; oophorectomy also reduces the risk for breast cancer), or both surg ...
... BRCA1 or BRCA2 mutations: chemoprevention (tamoxifen for breast cancer and oral contraceptives for ovarian cancer), prophylactic surgery (bilateral mastectomy for breast cancer and bilateral salpingo-oophorectomy for ovarian cancer; oophorectomy also reduces the risk for breast cancer), or both surg ...
What you should know about genes and cancer
... There are several types of genetic tests, and interpretation of the results depends on which test was ordered. Your blood relatives may have the same mutation and may also have a high risk for cancer, so it is important to share information about your genetic counseling and testing result. A positiv ...
... There are several types of genetic tests, and interpretation of the results depends on which test was ordered. Your blood relatives may have the same mutation and may also have a high risk for cancer, so it is important to share information about your genetic counseling and testing result. A positiv ...
The Changing View of High-Grade Serous Ovarian Cancer
... early estimates of the TP53 mutation rate in ovarian cancer varied widely (10), in part because many studies aggregated different histotypes. By narrowing our focus to a specific histotype, we were able to show that TP53 gene mutations occur in almost 100% of HGSCs (11). Germline and somatic mutation ...
... early estimates of the TP53 mutation rate in ovarian cancer varied widely (10), in part because many studies aggregated different histotypes. By narrowing our focus to a specific histotype, we were able to show that TP53 gene mutations occur in almost 100% of HGSCs (11). Germline and somatic mutation ...
MLH1: Hereditary non-polyposis colon cancer (HNPCC)
... MLH1: Hereditary nonpolyposis colon cancer (HNPCC) ...
... MLH1: Hereditary nonpolyposis colon cancer (HNPCC) ...
studentship project proposal - Institute of Cancer Research
... who are at highest risk of developing breast cancer due to environmental causes are those who previously have been treated for Hodgkin lymphoma (HL) with radiotherapy at a young age (1). Breast cancer risk in this group is elevated 20-fold above the general population and is similar to that of BRCA ...
... who are at highest risk of developing breast cancer due to environmental causes are those who previously have been treated for Hodgkin lymphoma (HL) with radiotherapy at a young age (1). Breast cancer risk in this group is elevated 20-fold above the general population and is similar to that of BRCA ...
Panel Testing for Familial Breast Cancer: Calibrating the Tension
... role for that particular gene. In this study, when applied to a large group of women affected by breast cancer with the highest risk of carrying a clear genetic cause, the use of a multigene panel in a research setting has provided important clinical information to 34 families: 26 with a pathogenic ...
... role for that particular gene. In this study, when applied to a large group of women affected by breast cancer with the highest risk of carrying a clear genetic cause, the use of a multigene panel in a research setting has provided important clinical information to 34 families: 26 with a pathogenic ...
Genetic Testing for Hereditary Breast and/or Ovarian Cancer
... Two breast primary cancers include cancers appearing at the same time (synchronous) and one is not a metastasis of the other; or primary cancers developing at different times (metachronous or asynchronous). The tumors may be in one or two breasts. Gleason scoring is a system of grading prostate canc ...
... Two breast primary cancers include cancers appearing at the same time (synchronous) and one is not a metastasis of the other; or primary cancers developing at different times (metachronous or asynchronous). The tumors may be in one or two breasts. Gleason scoring is a system of grading prostate canc ...
BREAST CANCER RESEARCH
... 10. http://www.cancer.org/research/acsresearchupdates/breast-cancer-research 11. Simon, C. E. (2006). "Breast cancer screening: cultural beliefs and diverse populations." Health Soc Work 31(1): 36-43. 12. Thompson, H. S., et al. (2004). "The Group-Based Medical Mistrust Scale: psychometric propertie ...
... 10. http://www.cancer.org/research/acsresearchupdates/breast-cancer-research 11. Simon, C. E. (2006). "Breast cancer screening: cultural beliefs and diverse populations." Health Soc Work 31(1): 36-43. 12. Thompson, H. S., et al. (2004). "The Group-Based Medical Mistrust Scale: psychometric propertie ...
What`s new in Breast Disease - Grand Strand Advanced Practice
... Originally approved as add-on only FDA 2013-approved for use without standard 2-D mammography Provides images of the breast in “slices” from many different angles Not always covered by insurance Machines cost 2x as much ...
... Originally approved as add-on only FDA 2013-approved for use without standard 2-D mammography Provides images of the breast in “slices” from many different angles Not always covered by insurance Machines cost 2x as much ...
Genetic Testing 101: Identifying High Risk Individuals
... Unaffected family members may not need Management based on personal/family history ...
... Unaffected family members may not need Management based on personal/family history ...
ECG ASCO Ovarian Symposium - Educational Concepts Group
... Conclusions • High-grade serous ovarian cancer is a disease of genomic chaos • BRCA/Fanconi pathway/HRD testing is reasonable for all patients with ovarian cancer • Mutational analysis of tumors can be considered but will not alter initial management and can be used only for clinical trial identifi ...
... Conclusions • High-grade serous ovarian cancer is a disease of genomic chaos • BRCA/Fanconi pathway/HRD testing is reasonable for all patients with ovarian cancer • Mutational analysis of tumors can be considered but will not alter initial management and can be used only for clinical trial identifi ...
Title A new paradigm of genetic testing for hereditary breast/ovarian
... cancer genetic counselling/testing were selected. of high-risk patients and their families. Individuals The search terms used were “familial breast/ovarian with hereditary breast/ovarian cancer will benefit cancer”, “susceptibility genes”, “genetic counselling”, from genetic counselling/testing. and ...
... cancer genetic counselling/testing were selected. of high-risk patients and their families. Individuals The search terms used were “familial breast/ovarian with hereditary breast/ovarian cancer will benefit cancer”, “susceptibility genes”, “genetic counselling”, from genetic counselling/testing. and ...
Lung cancer - Circulating Tumor DNA (ctDNA)
... that cause NSCLC These mutations are patient-specific These mutations can be detected by molecular studies of : tumor (biopsy) blood (liquid biopsy) ...
... that cause NSCLC These mutations are patient-specific These mutations can be detected by molecular studies of : tumor (biopsy) blood (liquid biopsy) ...
File
... • The following statements about breast cancer evaluation are true EXCEPT: A. Mammography can miss up to 10-15% of breast cancers B. FNAB and needle core biopsy provide identical results C. US bx is not useful for evaluation of microcalcifications D. Stereotactic core bx is the modality of choice fo ...
... • The following statements about breast cancer evaluation are true EXCEPT: A. Mammography can miss up to 10-15% of breast cancers B. FNAB and needle core biopsy provide identical results C. US bx is not useful for evaluation of microcalcifications D. Stereotactic core bx is the modality of choice fo ...
Society of Gynecologic Oncology statement on risk
... patent on the BRCA1 and BRCA2 genes and therefore the vast majority of testing in the US was performed by their commercial testing facility at a cost of approximately $3000 and up to $4000 for the most comprehensive panel. The Court decided that specific proprietary methodology in genetic testing and ...
... patent on the BRCA1 and BRCA2 genes and therefore the vast majority of testing in the US was performed by their commercial testing facility at a cost of approximately $3000 and up to $4000 for the most comprehensive panel. The Court decided that specific proprietary methodology in genetic testing and ...
BRCA2
BRCA2 and BRCA2 (/ˌbrækəˈtuː/) are a human gene and its protein product, respectively. The official symbol (BRCA2, italic for the gene, nonitalic for the protein) and the official name (breast cancer 2, early onset) are maintained by the HGNC. Orthologs, styled Brca2 and Brca2, are common in other mammal species. BRCA2 is a human tumor suppressor gene (specifically, a caretaker gene), found in all humans; its protein, also called by the synonym breast cancer type 2 susceptibility protein, is responsible for repairing DNA.BRCA2 and BRCA1 are normally expressed in the cells of breast and other tissue, where they help repair damaged DNA or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double strand breaks. If BRCA1 or BRCA2 itself is damaged by a BRCA mutation, damaged DNA is not repaired properly, and this increases the risk for breast cancer. Thus, although the terms ""breast cancer susceptibility gene"" and ""breast cancer susceptibility protein"" (used frequently both in and outside the medical literature) sound as if they describe a proto-oncogene or oncogene, BRCA1 and BRCA2 are ""normal""; it is their mutation that is abnormal.The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 (13q12.3). The human reference BRCA 2 gene contains 28 exons, and the cDNA has 10,254 base pairs coding for a protein of 3418 amino acids.The gene was first cloned by scientists at Myriad Genetics, Endo Recherche, Inc., HSC Research & Development Limited Partnership, and the University of Pennsylvania.Methods to diagnose the likelihood of a patient with mutations in BRCA1 and BRCA2 getting cancer were covered by patents owned or controlled by Myriad Genetics. Myriad's business model of exclusively offering the diagnostic test led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012; it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.